Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23760241 | 0.85 | HIF1A (0.43) | HIF1ASMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL20664871 | 0.82 | HIF1A (0.44) | HIF1ASMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL20385183 | 0.79 | RAB9A (0.38) | HIF1ASMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL21591572 | 0.78 | HIF1A (0.39) | HIF1AKMT2AHPGDMEN1HSD17B10 | |
| SCHEMBL21142493 | 0.77 | PDE4A (0.49) | SMN1; SMN2ALDH1A1ADORA2AADORA1PDE4A | |
| SCHEMBL22606405 | 0.76 | HIF1A (0.43) | HIF1A | |
| SCHEMBL7152983 | 0.75 | HIF1A (0.37) | HIF1ALTA4HBACE1 | |
| SCHEMBL7196866 | 0.75 | HIF1A (0.37) | HIF1ALTA4H | |
| SCHEMBL4863671 | 0.74 | HIF1A (0.36) | HIF1AKMT2ALTA4H | |
| SCHEMBL256361 | 0.74 | LTA4H (0.41) | HIF1ARAB9ANPC1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753381-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230242550-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | GENENTECH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230142338-A1 | THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-11643421-B2 | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer | GENENTECH, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2023069613-A1 | ARYLIMIDAMIDES FOR USE IN TREATMENT OF CANCERS | OHIO STATE INNOVATION FOUNDATION (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022268025-A1 | ATR INHIBITOR AND USE THEREOF | 成都苑东生物制药股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-20210379033-A1 | METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTS | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-12-09 | — | — | US | disclosed |
| US-20210179625-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND USES THEREOF | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-06-17 | — | — | US | disclosed |
| US-20210094921-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-04-01 | — | — | US | disclosed |
| US-20200338132-A1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2020-10-29 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| WO-2009143156-A2 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SEPRACOR INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| US-20090176757-A1 | Bicyclic Spirohydantoin CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-07-09 | — | — | US | disclosed |
| US-20090176757-A1 | Bicyclic Spirohydantoin CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-07-09 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20080096878-A1 | CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headaches; 2-(5-Bromo-1'1'-dioxido-2-oxo-2',3',5',6'-tetrahydrospiro[indole-3,4'-thiopyran]-1 (2H)-yl)-N-(2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)acetamide for example; use with other drugs | MERCK SHARP & DOHME LLC | 2008-04-24 | — | — | US | disclosed |
| US-7202251-B2 | Bicyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202251-B2 | Bicyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-04-10 | — | — | US | disclosed |
| WO-2006002099-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643421-B2 | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer | PIK3CA, PIK3CD, PIK3CB | HIF1A 3993/4885SMN1; SMN2 3820/4885RAB9A 806/4885 |
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | HIF1A 815/4885SMN1; SMN2 4168/4885RAB9A 2543/4885 |
| US-11753381-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | HIF1A 2868/4885SMN1; SMN2 998/4885RAB9A 1248/4885 |
| US-20230242550-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | PIK3CA, PIK3CD, PIK3CB | HIF1A 3993/4885SMN1; SMN2 3820/4885RAB9A 806/4885 |
| US-20080096878-A1 | CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headaches; 2-(5-Bromo-1'1'-dioxido-2-oxo-2',3',5',6'-tetrahydrospiro[indole-3,4'-thiopyran]-1 (2H)-yl)-N-(2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)acetamide for example; use with other drugs | CALCB, BDKRB2, BDKRB1 | HIF1A 1149/4885SMN1; SMN2 4732/4885RAB9A 2776/4885 |
| US-20210379033-A1 | METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTS | AHR, ARNT, NCOR1 | HIF1A 686/4885SMN1; SMN2 4380/4885RAB9A 4598/4885 |
| US-20210094921-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | HIF1A 2868/4885SMN1; SMN2 998/4885RAB9A 1248/4885 |
| US-20230142338-A1 | THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, NSUN3, NSUN2 | HIF1A 2053/4885SMN1; SMN2 551/4885RAB9A 2739/4885 |
| US-20210179625-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND USES THEREOF | AHR, ARNT, AIPL1 | HIF1A 789/4885SMN1; SMN2 3918/4885RAB9A 4634/4885 |
| US-20200338132-A1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS | AHR, HCLS1, ARNT | HIF1A 390/4885SMN1; SMN2 1234/4885RAB9A 2938/4885 |
| US-20090176757-A1 | Bicyclic Spirohydantoin CGRP Receptor Antagonists | BDKRB1, BDKRB2, CALCRL | HIF1A 834/4885SMN1; SMN2 3633/4885RAB9A 1893/4885 |
| US-20090233897-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | HIF1A 4176/4885SMN1; SMN2 4477/4885RAB9A 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.